Trial reportScientific reports2025
Efficacy of compound betamethasone combined with ropivacaine in iliac fascial space nerve block analgesia.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the anesthetic efficacy of ropivacaine combined with compound betamethasone in iliac fascial space nerve block analgesia (IFNBA) in patients receiving artificial femoral head replacement (AFHR), and to provide a theoretical basis for the selection of clinical anesthetic drugs. From January 2022 to June 2022, 70 patients requiring IFNBA analgesia undergoing AFHR surgery at our hospital were included in this prospective study. Using Excel randomization, 70 patients were divided into study group (n = 35) and control group (n = 35). The study group received ropivacaine combined with compound betamethasone analgesia regimen, while the control group only received ropivacaine analgesia regimen. In addition to patients' general baseline clinical characteristics, outcomes indicators included preoperative and postoperative visual analogue scale (VAS) pain scores, preoperative and postoperative Ramsay sedation scores, preoperative and postoperative levels of inflammatory cytokines, duration of analgesia and patient satisfaction in both groups were collected. At 12 h and 24 h after surgery, the static and dynamic VAS pain score of the study group was significantly lower than that of the control group (P < 0.05). At 6 h and 12 h after surgery, the Ramsay sedation score of the study group was significantly higher than that of the control group (P < 0.05). The level of inflammatory cytokines in the study group was significantly lower than that in the control group at the completion of surgery, 24 h and 72 h after surgery (P < 0.05). In addition, the study group had a significantly longer duration of postoperative analgesia and significantly better patient satisfaction (P < 0.05). Especially for patients receiving AFHR, in IFNBA, ropivacaine combined with compound betamethasone has better analgesic effect, higher patient satisfaction, and can effectively reduce the level of inflammatory status, which is worthy of clinical application and promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.